Dry Age-Related Macular Degeneration – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Age-related macular degeneration (AMD) is a progressive, degenerative disorder that often causes a large scotoma in the central visual field which leads to fixation and reading problems.

Etiology-

Dry AMD is caused by the appearance of small yellow deposits called drusen, which form under the retina. These are accumulated waste products of the retina, which can grow in size. This can cause the retinal cells in the macula that process light to die, causing vision to become blurred.

There are three stages of dry AMD:1. Early-stage of dry AMD:

Early-stage of dry AMD: several small drusen or a few medium-sized drusen, usually no symptoms or vision loss.

The intermediate stage of dry AMD:  many medium-sized drusen or one or more large drusen require more light or contrast (sharpness between light and dark) for reading and other tasks

Advanced stage of dry AMD (geographic atrophy): affecting the fovea or centre of one’s vision,  large areas of damaged tissue causing central blind spots, difficulty in reading or recognizing faces.

Epidemiology-

Approximately 11 million individuals are affected with AMD in the United States (U.S.) alone, with a global prevalence of 170 million. AMD is thereby the leading cause of visual disability in the industrialized world and the third leading cause globally.  Ageing is the greatest risk factor; therefore, the prevalence of AMD in the U.S. is anticipated to increase to 22 million by the year 2050, while the global prevalence is expected to increase to 288 million by the year 2040.

 

The competitive landscape of Dry Age-Related Macular Degeneration includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Dry Age-Related Macular Degeneration across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Dry Age-Related Macular Degeneration Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Dry Age-Related Macular Degeneration – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          RPESC-RPE-4W           Luxa Biotechnology, LLC           Phase 1/2

2          unoprostone isopropyl   Sucampo Pharma Americas, LLC            Phase 2

3          MA09-hRPE      CHABiotech CO., Ltd     Phase 2

4          AAVCAGsCD59            Janssen Research & Development, LLC            Phase 1

5          GT005  Gyroscope Therapeutics Limited Phase 2

6          Risuteganib       Allegro Ophthalmics, LLC          Phase 2

7          Zimura  IVERIC bio, Inc. Phase 2/3

8          GEM103           Gemini Therapeutics, Inc.          Phase 1

9          ARC1905          Ophthotech Corporation Phase 1

10        ACU-4429         Kubota Vision Inc.         Phase 2/3